Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 441

Results For "IND"

6581 News Found

AstraZeneca launches up-skilling program iPHARMACY
News | September 15, 2022

AstraZeneca launches up-skilling program iPHARMACY

The company has partnered with Neethi, a Kerala state cooperative consumers federation limited company, to run this program in Kerala


Lupin receives Health Canada approval for Rymti
Drug Approval | September 14, 2022

Lupin receives Health Canada approval for Rymti

Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, and paediatric plaque psoriasis


ProBioGen receives Employer of the Future and the Top Service awards
News | September 14, 2022

ProBioGen receives Employer of the Future and the Top Service awards

They also noted ProBioGen's digitalization investments and strategy, as well as its support for its employees.


AIIA launches 6-week long Ayurveda Day 2022 Programme
News | September 13, 2022

AIIA launches 6-week long Ayurveda Day 2022 Programme

The programme will see participation from various ministries of the Government of India with the aim of 3Js – Jan Sandesh, Jan Bhagidari, and Jan Aandolan.


We will vaccinate 100% of the animals by 2025: Narendra Modi
Policy | September 13, 2022

We will vaccinate 100% of the animals by 2025: Narendra Modi

The Prime Minister addressed a major problem that is affecting the income of farmers which is the diseases of animals and emphasised that in this direction India is working towards universal vaccination of animals


Tata Memorial Centre suggests low-cost intervention for breast cancer
News | September 13, 2022

Tata Memorial Centre suggests low-cost intervention for breast cancer

If implemented across the world, it has the capability to save over 100,000 lives annually


Lonza appoints Daniel Palmacci as President of the Cell & Gene Division
People | September 13, 2022

Lonza appoints Daniel Palmacci as President of the Cell & Gene Division

He takes over leadership of Cell & Gene from Jean-Christophe Hyvert, enabling Jean-Christophe to increase his focus on his role as President of the Biologics Division


Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda  for urothelial cancer
Clinical Trials | September 13, 2022

Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda for urothelial cancer

Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab


Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA
Clinical Trials | September 12, 2022

Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA

Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022


Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone
Clinical Trials | September 12, 2022

Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone

In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials